The burden of pediatric diarrhea: a cross-sectional study of incurred costs and perceptions of cost among Bolivian families

BMC Public Health

Juan S Leon³  Volga Iñiguez²  Emily R Smith³  Fiona M Kelly³  Carter L Cowden³  Laura Danielle Wagner³  Sally R Embrey³  Paulina A Rebolledo¹  Rachel M Burke³ 

[1] Division of Infectious Diseases, Emory University School of Medicine, Atlanta, GA, USA;Instituto de Biología Molecular y Biotecnología, Universidad Mayor de San Andrés, La Paz, Bolivia;Hubert Department of Global Health, Emory University, Rollins School of Public Health, Mailstop 1518-002-7BB, 1518 Clifton Road NE, Claudia N Rollins Bldg. 6050, Atlanta, GA 30322, USA

关键词: Health economics;    Pediatrics;    Diarrhea;    Economic burden;    Societal costs;   

Others  :  1161974
DOI  :  10.1186/1471-2458-13-708

 received in 2013-01-07, accepted in 2013-07-17,  发布年份 2013

【 摘 要 】

Background

Worldwide, acute gastroenteritis represents an enormous public health threat to children under five years of age, causing one billion episodes and 1.9 to 3.2 million deaths per year. In Bolivia, which has one of the lower GDPs in South America, an estimated 15% of under-five deaths are caused by diarrhea. Bolivian caregiver expenses related to diarrhea are believed to be minimal, as citizens benefit from universal health insurance for children under five. The goals of this report were to describe total incurred costs and cost burden associated with caregivers seeking treatment for pediatric gastroenteritis, and to quantify relationships among costs, cost burden, treatment setting, and perceptions of costs.

Methods

From 2007 to 2009, researchers interviewed caregivers (n=1,107) of pediatric patients (<5 years of age) seeking treatment for diarrhea in sentinel hospitals participating in Bolivia’s diarrheal surveillance program across three main geographic regions. Data collected included demographics, clinical symptoms, direct costs (e.g. medication, consult fees) and indirect costs (e.g. lost wages).

Results

Patient populations were similar across cities in terms of gender, duration of illness, and age, but familial income varied significantly (p<0.05) when stratified on appointment type. Direct, indirect, and total costs to families were significantly higher for inpatients as compared to outpatients of urban (p<0.001) and rural (p<0.05) residence. Consult fees and indirect costs made up a large proportion of total costs. Forty-five percent of patients’ families paid ≥1% of their annual household income for this single diarrheal episode. The perception that cost was affecting family finances was more frequent among those with higher actual cost burden.

Conclusions

This study demonstrated that indirect costs due to acute pediatric diarrhea were a large component of total incurred familial costs. Additionally, familial costs associated with a single diarrheal episode affected the actual and perceived financial situation of a large number of caregivers. These data serve as a baseline for societal diarrheal costs before and immediately following the implementation of the rotavirus vaccine and highlight the serious economic importance of a diarrheal episode to Bolivian caregivers.

【 授权许可】

   
2013 Burke et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Perez-Vargas J, Isa P, Lopez S, Arias CF: Rotavirus vaccine: early introduction in Latin America-risks and benefits. Arch Med Res 2006, 37(1):1-10.
• [2]Hatt LE, Waters HR: Determinants of child morbidity in Latin America: a pooled analysis of interactions between parental education and economic status. Soc Sci Med 2006, 62(2):375-386.
• [3]CIA World Factbook: Bolivia. https://www.cia.gov/library/publications/the-world-factbook/geos/bl.html webcite
• [4]BOLIVIA: Ingreso Promedio Mensual Per Cápita Por Condición De Pobreza Según Tipo De Ingreso. 2000. http://www.ine.gob.bo/indice/indice.aspx?d1=0415&d2=6 webcite
• [5]Bolivia (Plurinational State of): health profile. http://www.who.int/gho/countries/bol.pdf webcite
• [6]Fischer TK, Anh DD, Antil L, Cat ND, Kilgore PE, Thiem VD, Rheingans R, Le Tho H, Glass RI, Bresee JS: Health care costs of diarrheal disease and estimates of the cost-effectiveness of rotavirus vaccination in Vietnam. J Infect Dis 2005, 192(10):1720-1726.
• [7]Ehrenkranz P, Lanata CF, Penny ME, Salazar-Lindo E, Glass RI: Rotavirus diarrhea disease burden in Peru: the need for a rotavirus vaccine and its potential cost savings. Rev Panam Salud Publica 2001, 10(4):240-248.
• [8]Podewils LJ, Antil L, Hummelman E, Bresee J, Parashar UD, Rheingans R: Projected cost-effectiveness of rotavirus vaccination for children in Asia. J Infect Dis 2005, 192(Suppl 1):S133-145.
• [9]WHO: Guidelines for estimating the economic burden of diarrhoeal disease with focus on assessing the costs of rotavirus diarrhoea. Geneva, Switzerland: World Health Organization; 2005.
• [10]Widdowson MA, Meltzer MI, Zhang X, Bresee JS, Parashar UD, Glass RI: Cost-effectiveness and potential impact of rotavirus vaccination in the United States. Pediatrics 2007, 119(4):684-697.
• [11]CIA World Factbook - Kenya. https://www.cia.gov/library/publications/the-world-factbook/geos/ke.html webcite
• [12]Tate JE, Rheingans RD, O’Reilly CE, Obonyo B, Burton DC, Tornheim JA, Adazu K, Jaron P, Ochieng B, Kerin T, et al.: Rotavirus disease burden and impact and cost-effectiveness of a rotavirus vaccination program in kenya. J Infect Dis 2009, 200:S76-84.
• [13]Flem ET, Latipov R, Nurmatov ZS, Xue Y, Kasymbekova KT, Rheingans RD: Costs of diarrheal disease and the cost-effectiveness of a rotavirus vaccination program in kyrgyzstan. J Infect Dis 2009, 200:S195-202.
• [14]CIA World Factbook - Vietnam. https://www.cia.gov/library/publications/the-world-factbook/geos/vm.html webcite
• [15]Rheingans RD, Constenla D, Antil L, Innis BL, Breuer T: Economic and health burden of rotavirus gastroenteritis for the 2003 birth cohort in eight Latin American and Caribbean countries. Rev Panam Salud Publica 2007, 21(4):192-204.
• [16]CIA World Factbook - Mexico. https://www.cia.gov/library/publications/the-world-factbook/geos/mx.html webcite
• [17]Centenari C, Gurgel RQ, Bohland AK, Oliveirac DMP, Faragherd B, Cuevas LE: Rotavirus vaccination in northeast Brazil: a laudable intervention, but can it lead to cost-savings? Vaccine 2010, 28:4162-4168.
• [18]CIA World Factbook - Brazil. https://www.cia.gov/library/publications/the-world-factbook/geos/br.html webcite
• [19]Russell S: The economic burden of illness for households in developing countries: a review of studies focusing on malaria, tuberculosis, and human immunodeficiency virus/acquired immunodeficiency syndrome. Am J Trop Med Hyg 2004, 71(Suppl 2):147-155.
• [20]Mendelsohn AS, Asirvatham JR, Mwamburi DM, Sowmynarayanan TV, Malik V, Muliyil J, Kang G: Estimates of the economic burden of rotavirus-associated and all-cause diarrhoea in Vellore, India. Trop Med Int Health 2008, 13(7):934-942.
• [21]MacIntyre UE, Villiers FPR: The economic burden of diarrheal disease in a tertiary level hospital, gauteng, south Africa. J Infect Dis 2010, 202(S1):S116-S125.
• [22]Wang X-Y, Riewpaiboon A, Seidlein L, Chen X-B, Kilgore PE, Ma J-C, Qi S-X, Zhang Z-Y, Hao Z-Y, Chen J-C, et al.: Potential cost-effectiveness of a rotavirus immunization program in rural china. CID 2009, 49:1202-1210.
• [23]Jin H, Wang B, Fang Z, Duan Z, Gao Q, Liu N, Zhang L, Qian Y, Gong S, Zhu Q, et al.: Hospital-based study of the economic burden associated with rotavirus diarrhea in eastern China. Vaccine 2011, 29:7801-7806.
• [24]Mast TC, DeMuro-Mercon C, Kelly CM, Floyd LE, Walter EB: The impact of rotavirus gastroenteritis on the family. BMC Pediatr 2009, 9:11. BioMed Central Full Text
• [25]Wielen MV, Giaquinto C, Gothefors L, Huelsse C, Huet F, Littmann M, Maxwell M, Talayero JM, Todd P, Vila MT, et al.: Impact of community-acquired paediatric rotavirus gastroenteritis on family life: data from the REVEAL study. BMC Fam Pract 2010, 11:22. BioMed Central Full Text
• [26]Smith ER, Rowlinson EE, Iniguez V, Etienne KA, Rivera R, Mamani N, Rheingans R, Patzi M, Halkyer P, Leon JS: Cost-effectiveness of rotavirus vaccination in Bolivia from the state perspective. Vaccine 2011, 29:6704-6711.
• [27]Melgar-Quinonez HR, Zubieta AC, MkNelly B, Nteziyaremye A, Gerardo MF, Dunford C: Household food insecurity and food expenditure in Bolivia, Burkina Faso And the Philippines. J Nutr 2006, 136(5):1431S-1437S.
• [28]Bolivia: Gasto Promedio Mensual No Alimentario De Los Hogares Por Condición De Pobreza Y Tipo De Gasto, 2000. Instituto Nacional de Estadistica; 2000. http://www.ine.gob.bo/ipc/ipcprecios.aspx#null webcite
• [29]Isakbaeva ET, Musabaev E, Antil L, Rheingans R, Juraev R, Glass RI, Bresee JS: Rotavirus disease in Uzbekistan: cost-effectiveness of a new vaccine. Vaccine 2007, 25(2):373-380.
• [30]Constenla DO, Linhares AC, Rheingans RD, Antil LR, Waldman EA, Da Silva LJ: Economic impact of a rotavirus vaccine in Brazil. J Health Popul Nutr 2008, 26(4):388-396.
• [31]Lorgelly PK, Joshi D, Mara MIG, Flood C, Hughes CA, Dalrymple J, Gray J, Mugford M: Infantile gastroenteritis in the community: a cost-of-illness study. Epidemiol Infect 2008, 136:34-43.
• [32]Jacobs P, Shane L, Fassbender K, Wang E, Moineddin R, Ford-Jones E: Economic analysis of rotavirus-associated diarrhea in the metropolitan Toronto and Peel regions of Ontario. Can J Infect Dis 2002, 13:3.
• [33]As C, Silva AD, Gessner BD, Seini E, Jaillard P, Badolo O, Ouattara F, Zongo S, Bationo F: Costs for households and community perception of meningitis epidemics in burkina faso. Clin Infect Dis 2009, 49:1520-1525.
• [34]Oliveira LH, Danovaro-Holliday MC, Andrus JK, Fillipis AMB, Marc-Alain Widdowson obot RS, Matus CR, Gentsch J, Network: Sentinel hospital surveillance for Rotavirus in Latin American and Caribbean countries. J Infect Dis 2009, 200(Suppl 1):S131-139.
• [35]Oliveira LH, Danovaro-Holliday MC, Matus CR, Andrus JK: Rotavirus vaccine introduction in the Americas: progress and lessons learned. Expert Rev Vaccines 2008, 7(3):345-353.
• [36]Oliveira LH, Danovaro-Holliday MC, Sanwogou NJ, Andrus JK, Tambini G, Ruiz-Matus C: Progress in the introduction of the Rotavirus Vaccine in Latin America and the Caribbean: Four years of accumulated experience. Pediatr Infect Dis 2011, 30(1):S61-66.